表紙
市場調査レポート

Dendreon Corporationの製品パイプライン分析

Dendreon Corporation - Product Pipeline Review - 2014

発行 Global Markets Direct 商品コード 224609
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
Dendreon Corporationの製品パイプライン分析 Dendreon Corporation - Product Pipeline Review - 2014
出版日: 2014年05月30日 ページ情報: 英文 32 Pages
概要

Dendreon Corporationは開発段階のバイオテクノロジー企業で、癌やその他の生命にかかわる疾患の治療用医薬品の開発を行っています。

当レポートでは、Dendreon Corporationにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Dendreon Corporationの基本情報

Dendreon Corporationの概要

  • 主要情報
  • 企業情報

Dendreon Corporation:R&Dの概要

  • 主な治療範囲

Dendreon Corporation:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Dendreon Corporation:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Dendreon Corporation:薬剤プロファイル

  • lapuleucel-t
  • D-3263
  • 炭酸脱水酵素IXを標的とする薬剤
  • 癌胎児性抗原を標的とする薬剤

Dendreon Corporation:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Dendreon Corporation:最近のパイプライン動向

Dendreon Corporation:休止中のプロジェクト

Dendreon Corporation:開発が中止されたパイプライン製品

  • UK-279276

Dendreon Corporation:企業発表

Dendreon Corporation:本社と子会社の所在地

Dendreon Corporation:主要製造設備

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC04886CDB

Global Markets Direct's, 'Dendreon Corporation - Product Pipeline Review - 2014', provides an overview of the Dendreon Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Dendreon Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Dendreon Corporation including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Dendreon Corporation's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Dendreon Corporation's pipeline products

Reasons to buy

  • Evaluate Dendreon Corporation's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Dendreon Corporation in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Dendreon Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Dendreon Corporation and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Dendreon Corporation
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Dendreon Corporation and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Dendreon Corporation Snapshot
    • Dendreon Corporation Overview
    • Key Information
    • Key Facts
  • Dendreon Corporation - Research and Development Overview
    • Key Therapeutic Areas
  • Dendreon Corporation - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Dendreon Corporation - Pipeline Products Glance
    • Dendreon Corporation - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Dendreon Corporation - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Dendreon Corporation - Drug Profiles
    • lapuleucel-t
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • D-3263
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting Carbonic Anhydrase IX
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug Targeting Carcinoembryonic Antigen
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Dendreon Corporation - Pipeline Analysis
    • Dendreon Corporation - Pipeline Products by Target
    • Dendreon Corporation - Pipeline Products by Route of Administration
    • Dendreon Corporation - Pipeline Products by Molecule Type
    • Dendreon Corporation - Pipeline Products by Mechanism of Action
  • Dendreon Corporation - Recent Pipeline Updates
  • Dendreon Corporation - Dormant Projects
  • Dendreon Corporation - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • UK-279276
  • Dendreon Corporation - Company Statement
  • Dendreon Corporation - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Dendreon Corporation - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Dendreon Corporation, Key Information
  • Dendreon Corporation, Key Facts
  • Dendreon Corporation - Pipeline by Indication, 2014
  • Dendreon Corporation - Pipeline by Stage of Development, 2014
  • Dendreon Corporation - Monotherapy Products in Pipeline, 2014
  • Dendreon Corporation - Phase II, 2014
  • Dendreon Corporation - Phase I, 2014
  • Dendreon Corporation - Preclinical, 2014
  • Dendreon Corporation - Pipeline by Target, 2014
  • Dendreon Corporation - Pipeline by Route of Administration, 2014
  • Dendreon Corporation - Pipeline by Molecule Type, 2014
  • Dendreon Corporation - Pipeline Products by Mechanism of Action, 2014
  • Dendreon Corporation - Recent Pipeline Updates, 2014
  • Dendreon Corporation - Dormant Developmental Projects,2014
  • Dendreon Corporation - Discontinued Pipeline Products, 2014
  • Dendreon Corporation, Subsidiaries
  • Dendreon Corporation, Key Manufacturing Facilities

List of Figures

  • Dendreon Corporation - Pipeline by Top 10 Indication, 2014
  • Dendreon Corporation - Pipeline by Stage of Development, 2014
  • Dendreon Corporation - Monotherapy Products in Pipeline, 2014
  • Dendreon Corporation - Pipeline by Top 10 Target, 2014
  • Dendreon Corporation - Pipeline by Top 10 Route of Administration, 2014
  • Dendreon Corporation - Pipeline by Top 10 Molecule Type, 2014
  • Dendreon Corporation - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top